

Echo IQ

CORPORATE PRESENTATION
ISSUED FEBRUARY 2022

Disclaimer & Forward Looking Statements

This presentation has been prepared by ECHOIQ Limited (Echo IQ / ASX:EIQ). This document contains background information about Echo IQ current at the date of this presentation, 4 February 2022. The presentation is in summary form and does not purport to be all inclusive or complete. Recipients should conduct their own investigations and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinions contained in this presentation.

This presentation is for information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sales of shares in any jurisdiction.

This presentation does not constitute investment advice and has been prepared without taking into account the recipient's investment objectives, financial circumstances or particular needs and the opinions and recommendations in this presentation are not intended to represent recommendations of particular investments to particular persons. Recipients should seek professional advice when deciding if an investment is appropriate. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

To the fullest extent permitted by law Echo IQ, its officers, employees, agents and advisors do not make any representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of any information, statements, opinions, estimates, forecasts or other representations contained in this presentation. No responsibility for any errors or omissions from this presentation arising out of negligence or otherwise are accepted.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions which are outside the control of Echo IQ. Actual values, results or events may be materially different to those expressed or implied in this presentation. Given these uncertainties, recipients are cautioned not to place reliance on forward looking statements. Any forward-looking statements in this presentation speak only at the date of issue of this presentation. Subject to any continuing obligations under applicable law, Echo IQ does not undertake any obligation to update or revise any information or any of the forward-looking statements in this presentation or any changes in events, conditions, or circumstances on which any such forward looking statement is based.




Echo IQ

**Reinventing cardiac diagnostics
using the power of
artificial intelligence**

Echo IQ Corporate Snapshot

SHARE PRICE 3 FEB, 2022	\$0.145
SHARES ON ISSUE	394,332,713
OPTIONS ISSUED	197,425,713*
MARKET CAPITALISATION	c.A\$57M
NET CASH BALANCE (Dec 2021)	A\$2.519M
(+ up to A\$1.46M in 3/4/5 cent options due by end June 2022)	
*Substantial proportion with aggressive targets before they vest	

ASX:EIQ



TOP 10 Shareholders - c.39% of Company
TOP 20 Shareholders - c.53% of Company

JUNE 2021

ACQUISITION OF ALERTE ECHO IQ
BY HOUSTON WE HAVE

OCTOBER 2021

STRATEGIC RE-STRUCTURE TO FOCUS
ON MEDTECH AND CARDIAC AI /
CLINICAL STUDIES ANNOUNCED

NOVEMBER 2021

COMPANY COMPLETES NAME
CHANGE TO ECHO IQ

JANUARY 2022

LEADERSHIP TEAM EXPANDED TO INCLUDE
MEDTECH PROFESSIONALS IN REGULATORY
AFFAIRS AND COMMERCIAL DEVELOPMENT

Investment Highlights

- 1 Echo IQ has developed novel technology and proprietary algorithms designed to transform diagnosis of structural heart diseases, starting with the leading form of valvular heart disease - aortic stenosis
- 2 Exclusive commercial access to NEDA (the world's largest and leading database of its kind) supports the current and future Echo IQ solutions portfolio
- 3 Targeting a highly lucrative market where Echocardiograms are routinely mis-interpreted and repeated, and treatment outcomes are highly successful
- 4 Low regulatory barriers to entry for maiden solutions, with clear pathways for longer term product deployment
- 5 Company re-named and re-structured (December 2021) to maximise commercial opportunities from Echo IQ
- 6 Maiden clinical studies of Echo IQ technology at St. Vincent's Hospitals in Sydney and Melbourne being fully-funded by Edwards LifeSciences (NYSE:EW US\$70B)

What's the problem?



More people die from cardiovascular disease every year than any other cause. It claims the lives of 18 million people annually.

Whilst treatment options have never been better, mis-diagnosis and under-diagnosis remain common.

In Australia, for example, it is estimated that half of all people with heart valve disease don't even know they have it.

How Does Echo IQ help?

Echo IQ uses its AI-driven technology to enhance the diagnosis of structural heart disease.

The company's algorithms, developed using advanced data science and machine learning, utilise world-leading cardiac big data.

Our mission is to help reduce the number of patients currently being missed for life-saving and extending treatments.



Access to world-leading cardiac Big Data

Lack of access to large and highly relevant medical datasets has been a significant obstacle to transformational AI innovation in healthcare.

However.

Echo IQ has a 17 year (7+10) agreement with the National Echo Database of Australia (NEDA) for EXCLUSIVE commercial access to the world's largest database of echocardiographic measurements (linked to mortality).

The NEDA research database has been developed over more than 6 years, is internationally recognised.



1.8M

**Patients'
Records**

200M

**Cardiac
Datapoints**



**Mortality
Linked**

NEDA Sponsorship Partners




Edwards Lifesciences



Echo IQ

How BigData and AI can make healthcare MORE human



In DEEP MEDICINE, leading physician Eric Topol reveals how artificial intelligence can help make healthcare human again.

He explains how AI has the potential to transform everything doctors do, from note-taking and medical scans to diagnosis and treatment, greatly **cutting down the cost of medicine and reducing human mortality.**

By freeing physicians from the tasks that interfere with human connection, Topol foresees how **AI will create space for the real healing that takes place between a doctor who can listen and a patient who needs to be heard.**

#impactinvesting
#aiforgood

Introducing Echo IQ Enhanced Screening Program (ESP)



A proprietary AI-backed system that identifies patients **at risk of mortality** from structural heart disease.

Assistive technology that also gives cardiologists extra time to care for their patients. A support tool for cardiologists, not a replacement.



Our **flagship solution** is designed to address under and mis-diagnosis in Aortic Stenosis, the highly treatable but most common form of heart valve disease.

In a published validation study, Echo IQ ESP identified **100%** of in-guideline patients with Aortic Stenosis, and an **ADDITIONAL** population at risk of mortality from AS **at least as large again**.

Commercial Roadmap - Initial focus on US

More than 20M
Echocardiograms are
performed, at an average
cost of US\$2500, in the
US annually

20M

The US has more
practicing
cardiologists than any
other country

31,050

TAVR replacements
and associated
hospitalisation
estimated at more than
\$3.5bn per year

\$3.5bn

Revenue Sources: Echo IQ ESP

		Solution Integration	Regulatory Settings	Timeframe
1	RETROSPECTIVE ASSESSMENT	Software & Reporting	Potentially Excluded from FDA oversight or subject to 510(k) Clearance*	H2 2022 - H1 2023
2	REAL-TIME PROFILING + REPORTING INTEGRATION	Software & Reporting	Potentially Excluded from FDA oversight or subject to 510(k) Clearance*	H1 2023
3	SCREENING GUIDANCE IN REAL TIME	Hardware	Subject to FDA Oversight	H2 2023 +

**Regulatory Consultants advise some versions of ESP could sit outside the FDA oversight framework, or within the 510(k) clearance protocols but investigating commercial benefits of pursuing voluntary clearance*

Retrospective Assessment Market Sizing

20M

Echocardiograms performed
in the US annually

60M

Three year "recent archive"
available for ESP review

\$10M

Attainable revenue from scanning
100,000 at \$100 each
(0.17% of 3yr archive)

Retrospective Assessment would give clinics and hospitals the ability to apply another layer of analysis to echocardiographic measurement data captured in the previous, week, month or even year.

Patients flagged as exhibiting the AS risk phenotype could be prioritised for further assessment or surgical therapies.

Real-Time Profiling

Market Sizing



20M

Echocardiograms performed
in the US annually



\$10M

Attainable revenue from
scanning 100,000 at \$100 each
(0.5% of mkt)

Real-Time Profiling would give clinics and hospitals the ability to apply another layer of analysis to echocardiographic measurement data captured as echo's are performed.

Patients flagged as exhibiting the AS risk phenotype could be prioritised for further assessment or surgical therapies.

How Patients benefit from



**For every
100,000
Echo Records
Assessed**

Patient Benefits

Our data indicates that **c. 2,500** (2.5%) are currently receiving valve replacements.

However, our solution identifies an **additional cohort of c. 2,500** that suffers from (in-guideline) severe AS that is currently NOT receiving treatment.

Our AI also identifies a third group, similar in size at **c. 2,500 that is at risk of death** from aortic stenosis (and would benefit from valve replacement that is missed by current guidelines).

Relevant Evidence

Playford D, Bordin E, Mohamad R, et al.

Enhanced Diagnosis of Severe Aortic Stenosis Using Artificial Intelligence: A Proof-of-Concept Study of 530,871 Echocardiograms. JACC Cardiovasc Imaging 2020;13(4):1087-90. doi: 10.1016/j.jcmg.2019.10.013

Baker Insitute: White Paper
Time to Listen to the Heart, 2021

Validation Study on Risk Identification of AS phenotype in 330,000 patients

**Patient Benefits figures indicative only, based on internal data as well as published research in JACC and JACC Imaging Journals 2019.*

Echo IQ

How HealthCare Sector benefits from

**Per 100,000
Echo Records
Assessed**

Sector Impacts

Reduction in emergency presentations, with improved ability to plan treatment

Up to \$137M in incremental replacement valve sales*
(vs \$10M in additional scanning fees)

Up to \$100M in incremental surgery and hospital fees*
(vs \$10M in additional scanning fees)

Relevant Evidence

Validation Study on Risk Identification of AS phenotype in 330,000 patients

**Baker Insitute: White Paper
Time to Listen to the Heart, 2021**

**Figures indicative only, based on internal data as well as published research in JACC and JACC Imaging Journals 2019.*

Progress to commercialisation

Clinical Application Study

Retrospective observation and evaluation study

- St Vincent's Sydney & Melbourne
- NEDA + Echo IQ + Extential
- Fully funded by Edwards LifeSciences*

**NYSE:EW / Mkt. Cap. US\$70B
World's largest replacement aortic valve maker*

Commenced Q4 2021
Expected conclusion Q2 2022

Commercial MedTech Team Build-Out

Commercial Lead with 20yrs MedTech & US experience

> Recruited / Start March '22

International Regulatory Affairs (Medical) Lead

> Recruited / Start March '22

Expand Medical Advisory Board (US focus)

> Q2 2022

Who are we talking to?

Replacement Valve Manufacturers	Echocardiography Equipment Makers	PACS & Reporting Software Suppliers	Cardiologists and Surgical Centres	Insurance Providers
Valve manufacturers benefit from additional suitable patients identified by Echo IQ's ESP.	Added value services that help turn a one-time hardware sale into a source of recurring subscription and SAAS revenues.	Enhancements that differentiate PACS suppliers from competitors, and increase value to clinicians.	Systems that increase suitable candidates for AVR procedures are commercially valuable to this community.	Early identification of risk, and the ability to treat, reduces ongoing care costs and improves health outcomes.

Echo IQ: Technology designed to leave no patient behind

Where to from here?

- 1 Receiving data from clinical study sites (St. Vincent's Sydney and Melbourne) with anticipated study conclusion approx. May 2022.
- 2 Leveraging early interest from key players in the global valve, hardware and software sectors with plans for pilots, new test sites and commercial collaboration.
- 3 Accelerating US commercialisation, focussing on leading cardiology clinics and hospital groups - to be driven by new Chief Commercial Officer commencing March 2022.
- 4 Advancing software and reporting integration development work by extending collaboration with Extential in two test sites, running in real-time.
- 5 Progressing pathways to regulatory clearances and/or exclusions under the leadership of a newly appointed VP Regulatory Affairs.
- 6 Incorporating newly acquired data from NEDA into our solutions suite with focus on other forms of structural heart disease beyond aortic stenosis.



Echo IQ

**Reinventing cardiac diagnostics
using the power of
artificial intelligence**

**ASX: EIQ
echoiq.ai**